[
  {
    "ts": "2026-01-05T02:11:14+00:00",
    "headline": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
    "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "713d8659-f86f-3e1c-869b-d0977f5d29e8",
      "content": {
        "id": "713d8659-f86f-3e1c-869b-d0977f5d29e8",
        "contentType": "STORY",
        "title": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
        "description": "",
        "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
        "pubDate": "2026-01-05T02:11:14Z",
        "displayTime": "2026-01-05T02:11:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]